Oct 09 2026 This Week in Cardiology

Listener feedback on POET II, sham control trials in atrial fibrillation, ICDs in HCM, and agenda laundering are the topics John Mandrola, MD, discusses in this week's podcast.This podcast is intended for healthcare professionals only.To read a partial transcript or to comment, visit:https://www.medscape.com/twicI Listener FeedbackPOET II Response-Tailored or Standard-Duration ABX for Infectious EndocarditisPOET I Trial https://www.nejm.org/doi/10.1056/NEJMoa1808312POET II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607887II PVI-SHAM-AF trial Back in the NewsGAP-AF Trial https://www.ahajournals.org/doi/10.1161/circep.115.003337PVI-SHAM-AF Trial 10.1016/S0140-6736(26)01558-8 External LinkWhy Sham Studies Are a Sham in 2026 10.1016/j.hrthm.2026.09.056 External LinkThe Indispensable Role of Sham Controls in Evaluating Interventional Therapies 10.1016/j.hrthm.2026.10.001 External LinkIII ICDs in HCMI CDs for the Prevention of SCD in High-Risk Patients with HCM https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.078597ICDs in HCM: Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079687IV Agenda LaunderingHow Commercial “Agenda Laundering” Shapes Critical Care https://www.bmj.com/content/395/bmj-2026-100963The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harringtonQuestions or feedback, please contact news@medscape.net Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.